Sino Biopharmaceutical (HKG:1177) obtained marketing approval for its Benmelstobart Injection in combination with Anlotinib Hydrochloride Capsule to treat patients with recurrent or metastatic endometrial cancer from China's National Medical Products Administration, a Wednesday bourse filing said.
This is the second indication approved for the Benmelstobart Injection and the seventh indication approved for the Anlotinib Hydrochloride Capsule in China, according to the pharmaceutical firm.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments